Amyloid pathology is a key feature of Alzheimer’s disease (AD) and can be assessed in vivo with amyloid positron emission tomography (PET) imaging.
Objective:
The objective of this study was to evaluate the incremental value of a PET scan with [18F]florbetaben, in terms of changes of diagnosis, diagnostic confidence, and treatment plan when added to a standardized diagnostic workup for cognitive disorders, with particular focus on the role of the neuropsychological assessment, including the Free and Cued Selective Reminding Test (FCSRT).
Methods:
A total of 104 patients (69 mild cognitive impairment, 35 dementia), with diagnostic uncertainty after diagnostic workup, were recruited from our memory clinic. [18F]florbetaben PET scans were interpreted as amyloid negative or positive on the basis of a semi-quantitative visual rating. Clinical diagnosis and diagnostic confidence for AD or non-AD dementia were rated before and after PET result disclosure, as was the impact of PET on the patient management plan.
Results:
There were 69/104 (66%) [18F]florbetaben positive scans, 51/62 (82%) patients were suspected as having AD before the PET scan and 18/42 (43%) were not. Overall, the data obtained at PET changed 18/104 diagnoses (17%) and increased diagnostic confidence from 69.1±8.1% to 83.5±9.1 (p < 0.001), with the greatest impact on diagnosis and confidence in PET negative patients with an initial diagnosis of AD (p < 0.01) and in early-onset patients (p = 0.01).
Conclusion:
Amyloid PET represents a source of added value in dementia diagnosis, with a significant effect on diagnosis and diagnostic confidence. However, the use of a complete neuropsychological assessment has an add-on value on limiting the amyloid PET influence on change of diagnosis, and the real impact of amyloid PET should always be weighed up together with an accurate standardized diagnostic workup.
PalmqvistS, ZetterbergH, MattssonN, JohanssonP; Alzheimer’s Disease Neuroimaging Initiative, MinthonL, BlennowK, OlssonM, HanssonO; Swedish BioFINDER Study Group (2015) Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology85, 1240–1249.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
LeuzyA, ChiotisK, HasselbalchSG, RinneJO, de MendonçaA, OttoM, LleóA, Castelo-BrancoM, SantanaI, JohanssonJ, Anderl-StraubS, von ArnimCA, BeerA, BlesaR, ForteaJ, HerukkaSK, PorteliusE, PanneeJ, ZetterbergH, BlennowK, NordbergA (2016) Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study. Brain139, 2540–2553.
6.
DriscollI, TroncosoJC, RudowG, SojkovaJ, PletnikovaO, ZhouY, KrautMA, FerrucciL, MathisCA, KlunkWE, O’BrienRJ, DavatzikosC, WongDF, ResnickSM (2012) Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathol124, 823–831.
7.
CliffordR, JackCRJr, BarrioJR, KepeV (2013) Cerebral amyloid PET imaging in Alzheimer’s disease. Acta Neuropathol126, 643–657.
8.
JansenWJ, OssenkoppeleR, KnolDL, TijmsBM, ScheltensP, VerheyFR, VisserPJ; AmyloidBiomarker Study Group, AaltenP, AarslandD, AlcoleaD, AlexanderM, AlmdahlIS, ArnoldSE, BaldeirasI, BarthelH, van BerckelBN, BibeauK, BlennowK, BrooksDJ, van BuchemMA, CamusV, CavedoE, ChenK, ChetelatG, CohenAD, DrzezgaA, EngelborghsS, FaganAM, FladbyT, FleisherAS, van der FlierWM, FordL, FörsterS, ForteaJ, FoskettN, FrederiksenKS, Freund-LeviY, FrisoniGB, FroelichL, GabryelewiczT, GillKD, GkatzimaO, Gómez-TortosaE, GordonMF, GrimmerT, HampelH, HausnerL, HellwigS, HerukkaSK, HildebrandtH, IshiharaL, IvanoiuA, JagustWJ, JohannsenP, KandimallaR, KapakiE, Klimkowicz-MrowiecA, KlunkWE, KöhlerS, KoglinN, KornhuberJ, KrambergerMG, Van LaereK, LandauSM, LeeDY, de LeonM, LisettiV, LleóA, MadsenK, MaierW, MarcussonJ, MattssonN, de MendonçaA, MeulenbroekO, MeyerPT, MintunMA, MokV, MolinuevoJL, MøllergårdHM, MorrisJC, MroczkoB, Van der MusseleS, NaDL, NewbergA, NordbergA, NordlundA, NovakGP, ParaskevasGP, ParnettiL, PereraG, PetersO, PoppJ, PrabhakarS, RabinoviciGD, RamakersIH, RamiL, Resende de OliveiraC, RinneJO, RodrigueKM, Rodríguez-RodríguezE, RoeCM, RotU, RoweCC, RütherE, SabriO, Sanchez-JuanP, SantanaI, SarazinM, SchröderJ, SchütteC, SeoSW, SoeteweyF, SoininenH, SpiruL, StruyfsH, TeunissenCE, TsolakiM, VandenbergheR, VerbeekMM, VillemagneVL, VosSJ, van Waalwijk van DoornLJ, WaldemarG, WallinA, WallinÅK, WiltfangJ, WolkDA, ZbochM, ZetterbergH (2015) Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA313, 1924–1938.
9.
OssenkoppeleR, JansenWJ, RabinoviciGD, KnolDL, van der FlierWM, van BerckelBN, ScheltensP, VisserPJ; Amyloid PET Study Group, VerfaillieSC, ZwanMD, AdriaanseSM, LammertsmaAA, BarkhofF, JagustWJ, MillerBL, RosenHJ, LandauSM, VillemagneVL, RoweCC, LeeDY, NaDL, SeoSW, SarazinM, RoeCM, SabriO, BarthelH, KoglinN, HodgesJ, LeytonCE, VandenbergheR, van LaereK, DrzezgaA, ForsterS, GrimmerT, Sánchez-JuanP, CarrilJM, MokV, CamusV, KlunkWE, CohenAD, MeyerPT, HellwigS, NewbergA, FrederiksenKS, FleisherAS, MintunMA, WolkDA, NordbergA, RinneJO, ChételatG, LleoA, BlesaR, ForteaJ, MadsenK, RodrigueKM, BrooksDJ (2015) Prevalence of amyloid PET positivity in dementia syndromes: A meta-analysis. JAMA313, 1939–1949.
10.
JohnsonKA, MinoshimaS, BohnenNI, DonohoeKJ, FosterNL, HerscovitchP, KarlawishJH, RoweCC, CarrilloMC, HartleyDM, HedrickS, PappasV, ThiesWH; Alzheimer’s Association; Society of Nuclear Medicine and Molecular Imaging; Amyloid Imaging Taskforce (2013) Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement9, e1–16.
11.
JohnsonKA, MinoshimaS, BohnenNI, DonohoeKJ, FosterNL, HerscovitchP, KarlawishJH, RoweCC, HedrickS, PappasV, CarrilloMC, HartleyDM (2013) Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education. J Nucl Med54, 1011–1013.
12.
BarthelH, SabriO (2017) Clinical use and utility of amyloid imaging. J Nucl Med58, 1711–1717.
13.
FantoniER, ChalkidouA, O’ BrienJT, FarrarG, HammersA (2018) A systematic review and aggregated analysis on the impact of amyloid PET brain imaging on the diagnosis, diagnostic confidence, and management of patients being evaluated for Alzheimer’s disease. J Alzheimers Dis63, 783–796.
GrundmanM, PontecorvoMJ, SallowaySP, DoraiswamyPM, FleisherAS, SadowskyCH, NairAK, SiderowfA, LuM, AroraAK, AgbulosA, FlitterML, KrautkramerMJ, SarsourK, SkovronskyDM, MintunMA, GroupAS (2013) Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord27, 4–15.
16.
BoccardiM, AltomareD, FerrariC, FestariC, GuerraUP, PagheraB, PizzocaroC, LussignoliG, GeroldiC, ZanettiO, CotelliMS, TurlaM, BorroniB, RozziniL, MirabileD, DefantiC, GennusoM, PrelleA, GentileS, MorandiA, VollaroS, VoltaGD, BianchettiA, ContiMZ, CappuccioM, CarboneP, BellandiD, AbruzziL, BettoniL, VillaniD, RaimondiMC, LanariA, CicconeA, FacchiE, Fazio IDi, RozziniR, BoffelliS, ManzoniL, SalviG Pietro, CavaliereS, BelottiG, AvanziS, PasqualettiP, MuscioC, PadovaniA (2016) Assessment of the incremental diagnostic value of Florbetapir F 18 imaging in patients with cognitive impairment: The incremental diagnostic value of amyloid PET with [18F]-Florbetapir (INDIA-FBP) Study. JAMA Neurol256, 184–192.
17.
FrederiksenKS, HasselbalchSG, HejlAM, LawI, HojgaardL, WaldemarG (2012) Added diagnostic value of (11)C-PiB-PET in memory clinic patients with uncertain diagnosis. Dement Geriatr Cogn Dis Extra2, 610–621.
18.
SchipkeCG, PetersO, HeuserI, GrimmerT, SabbaghMN, SabriO, HockC, KunzM, KuhlmannJ, ReiningerC, BlankenburgM (2012) Impact of beta-amyloid-specific florbetaben pet imaging on confidence in early diagnosis of Alzheimer’s disease. Dement Geriatr Cogn Disord33, 416–422.
19.
BensaidaneMR, BeauregardJM, PoulinS, ButeauFA, GuimondJ, BergeronD, VerretL, FortinMP, HoudeM, BouchardRW, SoucyJP, LaforceR (2016) Clinical utility of amyloid PET imaging in the differential diagnosis of atypical dementias and its impact on caregivers. J Alzheimers Dis52, 1251–1262.
20.
OssenkoppeleR, PrinsND, PijnenburgYA, LemstraAW, van der FlierWM, AdriaanseSF, WindhorstAD, HandelsRL, WolfsCA, AaltenP, VerheyFR, VerbeekMM, van BuchemMA, HoekstraOS, LammertsmaAA, ScheltensP, van BerckelBN (2013) Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement9, 414–421.
21.
WestonPSJ, PatersonRW, DicksonJ, BarnesA, BomanjiJB, KayaniI, LunnMP, MummeryCJ, WarrenJD, RossorMN, FoxNC, ZetterbergH, SchottJM (2016) Diagnosing dementia in the clinical setting: Can amyloid PET provide additional value over cerebrospinal fluid?J Alzheimers Dis54, 1297–1302.
22.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 271–279.
LitvanI, AgidY, JankovicJ, GoetzC, BrandelJP, LaiEC, WenningG, D’OlhaberriagueL, VernyM, ChaudhuriKR, McKeeA, JellingerK, BartkoJJ, MangoneCA, PearceRK (1996) Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology46, 922–930.
28.
BarthelH, LuthardtJ, BeckerG, PattM, HammersteinE, HartwigK, EggersB, SattlerB, SchildanA, HesseS, MeyerPM, WolfH, ZimmermannT, ReischlJ, RohdeB, GertzHJ, ReiningerC, SabriO (2011) Individualized quantification of brain beta-amyloid burden: Results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls. Eur J Nucl Med Mol Imaging38, 1702–1711.
29.
BarthelH, GertzHJ, DreselS, PetersO, BartensteinP, BuergerK, HiemeyerF, Wittemer-RumpSM, SeibylJ, ReiningerC, SabriO; Florbetaben Study Group (2011) Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: A multicentre phase 2 diagnostic study. Lancet Neurol10, 424–435.
30.
BoccardiM, GalloV, YasuiY, VineisP, PadovaniA, MosimannU, GiannakopoulosP, GoldG, DuboisB, Jack CRJr, WinbladB, FrisoniGB, AlbaneseE, Geneva Task Force for the Roadmap of Alzheimer’s Biomarkers (2017) The biomarker-based diagnosis of Alzheimer’s disease. 2-lessons from oncology. Neurobiol Aging52, 141–152.
31.
CaffarraP, GhettiC, RuffiniL, SpallazziM, SpottiA, BaroccoF, GuzzoC, MarchiM, GardiniS (2016) Brain metabolism correlates of the Free and Cued Selective Reminding Test in mild cognitive impairment. J Alzheimers Dis51, 27–31.
32.
Serrano-PozoA1, QianJ, MonsellSE, BlackerD, Gómez-IslaT, BetenskyRA, GrowdonJH, JohnsonKA, FroschMP, SperlingRA, HymanBT (2014) Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol75, 597–601.
33.
SabriO, SabbaghMN, SeibylJ, BarthelH, AkatsuH, OuchiY, SendaK, MurayamaS, IshiiK, TakaoM, BeachTG, RoweCC, LeverenzJB, GhettiB, IronsideJW, CatafauAM, StephensAW, MuellerA, KoglinN, HoffmannA, RothK, ReiningerC, Schulz-SchaefferWJ; Florbetaben Phase 3 Study Group (2015) Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: Phase 3 study. Alzheimers Dement11, 964–74.
34.
ZwanMD, BouwmanFH, KonijnenbergE, van der FlierWM, LammertsmaAA, VerheyFR, AaltenP, van BerckelBN, ScheltensP (2017) Diagnostic impact of [18F] Flutametamol in PET in early onset dementia. Alzheimers Res Ther9, 2.
35.
MendezMF, ShapiraJS, McMurtrayA, LichtE (2007) Preliminary findings: Behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry15, 84–87.
36.
ArciniegasDB, AndersonCA (2013) Donepezil-induced confusional state in a patient with autopsy-proven behavioral-variant frontotemporal dementia. J Neuropsychiatry Clin Neurosci25, E25–E26.
